China Standardizes Medical Testing Fees Under National Pricing Framework

China's National Healthcare Security Administration (NHSA) has released trial pricing guidelines for clinical laboratory tests, marking the completion of its 40-batch nationwide medical service pricing overhaul. Covering clinical tests, molecular diagnostics, biochemistry, and blood transfusions across 662 core items, the framework introduces standardized add-ons, tiered discounts for bundled tests, and fee reductions for missing digital records. The standardized pricing structure aims to eliminate redundant testing, promote cross-hospital result recognition, and regulate China's 130-billion-yuan in vitro diagnostics market.

A unified pricing baseline removes institutional hurdles to mutual recognition of diagnostic test results across hospitals and provinces. It lowers financial burdens on patients by penalizing redundant tests and mandating tiered package discounts, while establishing the final foundation for a nationwide medical pricing standard.

China's National Healthcare Security Administration (NHSA) has formally issued trial pricing guidelines for clinical laboratory testing, marking the completion of a nationwide initiative to standardize medical service fees across 40 distinct clinical categories, according to a report by People's Daily. The newly released guidelines cover major testing domains, including clinical laboratory examinations, blood transfusion and typing, microbiology and parasitology, molecular diagnostics, biochemistry, and immunology. In total, the document outlines 662 core pricing items, 114 add-on items, and seven extended items, creating a unified classification system for medical testing costs across China. Diagnostic testing serves as an essential foundation for clinical diagnosis, efficacy monitoring, and prognostic evaluation. Driven by expanding medical demand and continuous technological advancement, China's in vitro diagnostic (IVD) reagent market reached approximately 130 billion yuan ($18 billion) in 2025, representing a critical segment of the country's broader pharmaceutical and healthcare sector, an NHSA official noted. To address long-standing discrepancies in how hospitals bill for tests, the guidelines emphasize service-outcome-oriented pricing rather than pricing based solely on differing testing methodologies. The framework establishes standardized add-on charges to reflect high-quality care, unifies billing units, and formally institutes tiered discounts for bundled or joint testing panels to reduce the financial burden of redundant tests on patients. Additionally, the policy incorporates incentives for digital healthcare development by mandating price deductions for tests with missing or incomplete digital records, while simultaneously creating standardized categories to support new, innovative diagnostic techniques. NHSA officials stated that the agency will now guide provincial healthcare security authorities to calibrate local prices based on the 40 guidelines, aiming to achieve balanced regional pricing and consistent healthcare billing nationwide.